Skip to main content
Study

Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot?

Ellis RJ, Schlick CJR, Feinglass J, et al. Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot? BMJ Qual Saf. 2020;29(2):103-112. doi:10.1136/bmjqs-2019-009742.

Save
Print
September 18, 2019
Ellis RJ, Schlick CJR, Feinglass J, et al. BMJ Qual Saf. 2020;29(2):103-112.

This retrospective study of cancer care safety examined the extent to which patients received recommended chemotherapy. A significant proportion of breast, lung, and colorectal cancer patients did not receive chemotherapy; patients who were black and those lacking health insurance or covered by Medicaid were at higher risk. There was marked variability in chemotherapy delivery by location and hospital. The authors conclude that failure to administer chemotherapy is a significant safety gap that should be addressed.

Save
Print
Cite
Citation

Ellis RJ, Schlick CJR, Feinglass J, et al. Failure to administer recommended chemotherapy: acceptable variation or cancer care quality blind spot? BMJ Qual Saf. 2020;29(2):103-112. doi:10.1136/bmjqs-2019-009742.

Related Resources